Opportunities for efficiency in R&D | KPMG | UK

Opportunities for efficiency in R&D

Opportunities for efficiency in R&D

Most firms face a challenge of improving returns on investment in pharma R&D. Hasini Wijesuriya explains how they can achieve enhanced R&D efficiency.

1000

Partner

KPMG LLP (UK)

Contact

Also on KPMG.com

Opportunities for efficiency in R&D- microscope

Dr. Hasini Wijesuriya, Associate Director and Engagement Manager, Life Sciences Strategy Group and Prof. Hilary Thomas, Chief Medical Adviser, explains that new ways of understanding patients, their behaviour and their optimum outcomes might unlock a new era of R&D efficiency:

  • We’re entering a new phase driven by: patients’ self-articulated needs; new availability of data about their lifestyles; and the evolution of both payer and regulator expectations.
  • New technologies make it easier to address varied patient inputs, rather than snapshots from ‘expert’ or ‘professional’ patients;
  • Pharma firms that can react by placing patients fully at the heart of the R&D process should reap not only benefits for the people being treated – but also better return on investment on their processes and improved investor relations.

Find out more details by downloading our insight exploring the opportunities for efficiency in R&D.

Rethinking Life Sciences

Rethinking Life Sciences

Our insights page offers practical advice for leaders seeking agility, adaptability and fresh ideas in these crucial areas.

Partnering with patient groups

Partnering with patient groups

Developing mutually beneficial relationships between industry and patient representative bodies

Connect with us

 

Request for proposal

 

Submit